Corvus Pharmaceuticals(DE:C17)
€9.78-0.48 (-4.67%)
DE:C17
Corvus Pharmaceuticals earnings date
€9.78
At close:-0.48 (-4.67%)
Corvus Pharmaceuticals (C17) Q3 2026 Earnings Report
0 Followers
DE:C17 Q3 2026 EPS Results
- Actual EPS
- -EUR 0.20
- Consensus EPS
- -EUR 0.17
- Beat/Miss
- Missed by -EUR 0.03
- One Year Ago EPS
- -EUR 0.11
DE:C17 Q3 2026 Revenue Results
- Actual Revenue
- EUR 0
- Expected Revenue
- EUR 0
- Beat/Miss
- Met expectations
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/05/2026
- Time
- After Close
- Conference Call
- Thursday, November 5, 2026
DE:C17 Upcoming Earnings
Corvus Pharmaceuticals's next earnings date is estimated for March 24, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
DE:C17 Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was predominantly positive, with enrollment on track or ahead of plan across multiple programs, favorable early ALPS results, a strong cash position extending the operating runway into the second quarter of 2028, and several clinical milestones expected in 2027. The main negatives were increased R&D spending, a wider net loss, higher stock compensation, the modest extension of Angel's data timing, and the possibility that the PTCL trial could be stopped for futility.
Company Guidance
Based on cash, cash equivalents and marketable securities of $202.9 million as of September 30, 2026, Corvus expects its cash to fund operations into the second quarter of 2028; the Phase 3 PTCL futility analysis is anticipated in the first quarter of 2027 and top line data before the end of the year 2027, while SEERA-1 was planned to enroll approximately 200 patients across 3 soquelitinib doses and a placebo group with top line data anticipated in the third quarter of 27 and a potential Phase III start in 2028; ANGEL cohort 2 is expected to begin enrolling in November, with cohort 2 data potentially available in the second half of 2027, and an additional 60 to 90 patients anticipated in the Phase 2 portion; the HS Phase 1b trial is designed to enroll up to 25 patients and may report data in the first half of 2027; Corvus is on track to initiate the asthma trial in the first quarter of 2027, and both Corvus and Angel plan to launch asthma trials in 2027.
- Strong Cash Position and Extended Operating RunwayCash, cash equivalents and marketable securities totaled $202.9 million as of September 30, 2026, compared with $56.8 million at December 31, 2025. The balance included approximately $189.4 million in net proceeds from a follow-on offering completed in Q1. Based on its cash position and current plans, Corvus expects cash to fund operations into the second quarter of 2028.
- Soquelitinib Clinical Development ProgressSoquelitinib is being evaluated across several clinical trials. The company identified relapsed/refractory peripheral T cell lymphoma and moderate to severe atopic dermatitis as its two lead opportunities, with both programs described as on track.
- PTCL Phase 3 Enrollment on TrackEnrollment in the registrational Phase 3 trial in relapsed/refractory peripheral T cell lymphoma is on track with expectations. A futility analysis by an independent data monitoring committee is anticipated in the first quarter of 2027, and top-line Phase 3 data are expected before the end of 2027.
- Mechanistic Support from Memorial Sloan Kettering ResearchResearch using pre- and post-treatment biopsies from three patients with cutaneous T cell lymphoma associated response to soquelitinib with blocking GATA3 signaling, the master regulator of Th2 cells, and reducing Th2 cells in the skin. Management said the findings further support the drug's mechanism in both peripheral T cell lymphoma and atopic dermatitis.
- Atopic Dermatitis Phase 2 Trial on TrackThe SEERA-1 Phase 2 atopic dermatitis trial is planned to enroll approximately 200 patients across three soquelitinib doses and placebo, with a 12-week treatment period and a 90-day drug-free follow-up. Enrollment is on track, with top-line data anticipated in the third quarter of 2027. If successful, Corvus could start a Phase 3 program in 2028.
- Broad Atopic Dermatitis Patient EligibilityThe Phase 2 atopic dermatitis study accepts patients who have failed a topical corticosteroid or systemic therapy, including patients who have failed Dupixent, JAK inhibitors, other therapies, or systemic corticosteroids. Management stated that the company has not seen evidence of cross-resistance because soquelitinib's mechanism does not overlap with those therapies.
- Positive Progress in Angel Atopic Dermatitis TrialAngel Pharmaceuticals completed enrollment in Cohort 1 of its Phase 1b/2 atopic dermatitis trial, consisting of 24 patients randomized evenly to soquelitinib doses of 100 mg twice per day, 200 mg once per day, or placebo. Preliminary data are anticipated in March 2027 after 12 weeks of treatment and at least 30 days of post-treatment follow-up, while blinding will continue through the full 90-day follow-up.
- Potentially Relevant Asian Atopic Dermatitis BiologyAsian Americans represented 11%, or 8 of 72 patients, in Corvus' Phase 1 atopic dermatitis trial. Testing showed significantly elevated baseline serum IL-17 levels in these patients compared with the rest of the non-Asian population and healthy volunteers, consistent with a greater Th17 component described in the literature. Management said the Asian American patients had characteristics similar to patients enrolled in Angel's Chinese trial.
- Expansion of Angel Atopic Dermatitis DevelopmentAngel Pharmaceuticals expected to begin enrolling Cohort 2 in November 2026, with data potentially available in the second half of 2027. Cohort 2 will include 24 patients randomized evenly to soquelitinib doses of 200 mg twice per day, 400 mg once per day, or placebo. Depending on results from the first 48 patients in Cohorts 1 and 2, an additional 60 to 90 patients are anticipated in the Phase 2 portion.
- Hidradenitis Suppurativa Trial Ahead of Enrollment PlanCorvus initiated a Phase 1 trial in moderate to severe hidradenitis suppurativa in September. The trial can enroll up to 25 patients, all receiving 200 mg of soquelitinib twice per day for 12 weeks followed by a 90-day follow-up. Although the trial had been open for about one month, management said enrollment was ahead of plan, potentially supporting data in the first half of 2027.
- Hidradenitis Suppurativa Study Includes Multiple Efficacy and Biomarker MeasuresThe HS study's primary endpoint is safety and tolerability, with key efficacy endpoints including the proportion of patients achieving HiSCR 50 or HiSCR 75 at week 12. The study will also assess nodules, abscesses, draining tunnels, fibrosis, and skin and blood biomarkers involving Th17 cells, Th2 cells, Tregs, myeloid cells, and B cells. Management cited benchmark expectations of approximately 50% to 60% for HiSCR 50 and around 30% for HiSCR 75.
- Asthma Program Covers T2 and Non-T2 DiseaseCorvus plans to enroll both allergic or eosinophilic T2 asthma and non-T2 asthma, whereas management said most asthma drugs and trials address only T2 patients. The company cited that up to 40% of asthma patients have the non-T2 type. The trial is on track to begin in the first quarter of 2027 and will include an interim analysis that could discontinue a disease type for futility.
- ALPS Data Showed Responses and Favorable TolerabilityIn initial data from three ALPS patients treated for one year at 200 mg twice per day, all three patients completed treatment with no interruptions and no Grade 3 or 4 adverse events reported. All three discontinued background corticosteroids and immunosuppressive drugs, two of three had a reduction in circulating proliferating double-negative T cells, and splenomegaly was reduced in two of three patients.
- ALPS Program Transitioning to CorvusBased on the initial ALPS results, Corvus plans to transfer the soquelitinib IND from NIAID to Corvus, meet with the FDA to expand the number of treatment centers, and seek to reduce the age eligibility to include pediatric patients. The adult patients treated so far received 200 mg twice per day.
- Multiple 2027 Pipeline MilestonesExpected milestones include initial ALPS data at the ASH meeting in December, the PTCL futility analysis in the first quarter, Angel atopic dermatitis Cohort 1 data in March, HS Phase 1b results in the first half, SEERA-1 Phase 2 data in the third quarter, Angel Cohort 2 data in the second half, and PTCL Phase 3 top-line data before the end of 2027. Corvus and Angel also plan to launch asthma trials in 2027.
- Oral Therapy and Broad Immunomodulatory StrategyManagement described ITK inhibition as a mechanism that modulates several key cellular functions and resets the immune system through an oral tablet. The company said soquelitinib has so far shown a very favorable safety profile and is being developed across Th2- and Th17-driven diseases, including PTCL, atopic dermatitis, hidradenitis suppurativa, asthma, and ALPS.
DE:C17 Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 24, 2027 | 2026 (Q4) | -0.20- | -0.13 | ― | ― |
| Nov 05, 2026 | 2026 (Q3) | -0.17-0.20 | -0.11 | -83.33% (-0.09) | |
| Aug 06, 2026 | 2026 (Q2) | -0.14-0.17 | -0.09 | -90.00% (-0.08) | |
| May 07, 2026 | 2026 (Q1) | -0.13-0.13 | -0.12 | -15.38% (-0.02) | |
| Mar 12, 2026 | 2025 (Q4) | -0.12-0.13 | -0.16 | 16.67% (+0.03) | |
| Nov 04, 2025 | 2025 (Q3) | -0.11-0.11 | -0.54 | 80.00% (+0.43) | |
| Aug 07, 2025 | 2025 (Q2) | -0.12-0.09 | -0.06 | -42.86% (-0.03) | |
| May 08, 2025 | 2025 (Q1) | -0.11-0.12 | -0.11 | -8.33% (-0.01) | |
| Mar 25, 2025 | 2024 (Q4) | -0.10-0.16 | -0.13 | -28.57% (-0.04) | |
| Nov 12, 2024 | 2024 (Q3) | -0.10-0.54 | -0.11 | -400.00% (-0.43) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
